Wednesday, November 15, 2017 1:18:44 PM
https://www.fda.gov:80/FDAgov/NewsEvents/Newsroom/PressAnnouncements/ucm585308.htm
To follow KarinCA, click here then click "Follow This Member" under my photo.
Be kinder than necessary, for everyone you meet is fighting some kind of battle.
Recent RARE News
- Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update • GlobeNewswire Inc. • 05/02/2024 08:00:00 PM
- Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease • GlobeNewswire Inc. • 04/30/2024 08:00:00 PM
- Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update • GlobeNewswire Inc. • 04/25/2024 08:30:00 PM
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/19/2024 08:30:00 PM
- Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 • GlobeNewswire Inc. • 04/15/2024 11:00:00 AM
- Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome • GlobeNewswire Inc. • 04/12/2024 08:22:53 PM
- Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting • GlobeNewswire Inc. • 04/12/2024 12:00:00 PM
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/22/2024 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:23:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:22:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:17:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:15:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:13:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:10:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:08:18 AM
- Ultragenyx to Participate at Investor Conferences in March • GlobeNewswire Inc. • 02/27/2024 09:30:00 PM
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/23/2024 09:05:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/21/2024 10:03:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:04:29 PM
- Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update • GlobeNewswire Inc. • 02/15/2024 09:01:00 PM
- Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update • GlobeNewswire Inc. • 02/08/2024 09:00:00 PM
- Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome • GlobeNewswire Inc. • 02/05/2024 09:05:00 PM
- Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease • GlobeNewswire Inc. • 01/25/2024 09:05:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM